MedTrace Logo

GammaPod Registry and Quality of Life Nomogram

NCT03562273 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 160

Last updated 2026-02-20

No results posted yet for this study

Summary

This study is a prospective, single arm study (registry) summarizing patient-level adverse-event and tumor outcomes as well as a number of feasibility and dosimetric characteristics of delivering a single-fraction boost with the GammaPod.

Conditions

  • Breast Cancer Female

Interventions

RADIATION

Quality Of Life Sizing Nomogram

If the participant meets the eligibility criteria of the study, and participant chooses to take part, they will receive the tumor bed boost in 8 Gy in 1 fraction just prior to starting whole breast radiation after joining the study. Treatment to the whole breast will begin within 7-8 days from the TB boost (GammaPodTM) treatment. The radiation therapy will take approximately 6 weeks to complete. Follow-up visits specifically for this study will continue for one year, although the physician will continue to follow as part of routine care.

Sponsors & Collaborators

  • University of Texas, Southwestern Medical Center at Dallas

    collaborator OTHER

  • University of Maryland, Baltimore

    lead OTHER

Principal Investigators

  • Elizabeth M. Nichols, M.D. · University of Maryland

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-03
Primary Completion
2028-12-31
Completion
2030-12-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03562273 on ClinicalTrials.gov